Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
Monika Sahlgren
|
| gptkbp:country |
gptkb:Sweden
|
| gptkbp:developedBy |
melflufen
|
| gptkbp:focusesOn |
multiple myeloma
cancer therapeutics |
| gptkbp:founded |
2000
|
| gptkbp:headquarters_location |
gptkb:Stockholm
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oncopeptides
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Nasdaq_Stockholm
|
| gptkbp:notableProduct |
Pepaxto
|
| gptkbp:numberOfEmployees |
approximately 50 (2023)
|
| gptkbp:Pepaxto_approved_by |
gptkb:FDA
|
| gptkbp:Pepaxto_available_in |
gptkb:Europe
|
| gptkbp:Pepaxto_indication |
relapsed or refractory multiple myeloma
|
| gptkbp:Pepaxto_withdrawn_from_US_market |
2021
|
| gptkbp:stockExchange |
gptkb:Nasdaq_Stockholm
|
| gptkbp:stockSymbol |
ONCO
|
| gptkbp:website |
https://www.oncopeptides.com/
|
| gptkbp:bfsParent |
gptkb:HealthCap
|
| gptkbp:bfsLayer |
8
|